PMID: 11921109Mar 29, 2002Paper

Do risk factors for Alzheimer's disease predict dementia in Parkinson's disease? An exploratory study

Movement Disorders : Official Journal of the Movement Disorder Society
Gilberto LevyK Marder

Abstract

The extent to which concomitant Alzheimer's disease (AD) is etiologically related to the development of dementia in Parkinson's disease (PD) remains controversial. We explored the association of four risk factors associated with AD, including head injury, smoking, hypertension, and diabetes mellitus, with incident dementia in PD. A cohort of 180 nondemented PD patients from the Washington Heights community in northern Manhattan, New York, completed a risk factor questionnaire at baseline and was followed annually with neurological and neuropsychological evaluations. The association of baseline variables with incident dementia was analyzed by using Cox proportional hazards models. All analyses controlled for age at baseline, gender, years of education, duration of PD, and total Unified Parkinson's Disease Rating Scale (UPDRS) motor score at baseline. Of 180 patients (mean age, 71.0 +/- 10.3 years), 52 (29%) became demented during a mean follow-up period of 3.6 +/- 2.2 years. Head injury risk ratio ([RR] 0.9; 95% confidence interval [CI], 0.4-2.2; P = 0.9), hypertension (RR, 0.7; 95% CI, 0.4-1.4, P = 0.3), and diabetes mellitus (RR, 0.8; 95% CI, 0.3-2.3; P = 0.7) were not significantly associated with incident dementia in the Cox...Continue Reading

References

Feb 18, 1977·Science·S M Antelman, A R Caggiula
Jan 1, 1992·Psychopharmacology·E D Levin
Mar 1, 1992·Journal of Neurology, Neurosurgery, and Psychiatry·A J HughesA J Lees
May 1, 1991·Neurology·W C KollerA J Ruttenber
Jan 1, 1990·Movement Disorders : Official Journal of the Movement Disorder Society·K MarderR Mayeux
May 1, 1989·British Journal of Addiction·J Grenhoff, T H Svensson
Aug 1, 1988·Archives of General Psychiatry·J B Williams
Mar 1, 1994·Movement Disorders : Official Journal of the Movement Disorder Society·R MayeuxY Stern
Feb 1, 1993·Archives of Neurology·A J HughesA J Lees
May 1, 1993·Neurology·R M ZweigJ C Hedreen
Apr 27, 1996·Lancet·I SkoogA Svanborg
Jan 1, 1996·Neuroepidemiology·S L GlattW C Koller
Nov 1, 1996·Diabetologia·A OttM M Breteler
Feb 1, 1997·Journal of Neurology, Neurosurgery, and Psychiatry·P W SchofieldR Mayeux
Feb 15, 1997·American Journal of Epidemiology·C L LeibsonP J Palumbo
Jan 1, 1997·Journal of Neural Transmission. Supplementum·K A Jellinger
Mar 13, 1998·JAMA : the Journal of the American Medical Association·K YaffeD Grady
Apr 16, 1998·Alzheimer Disease and Associated Disorders·R InzelbergA D Korczyn
Aug 26, 1998·Drug and Alcohol Dependence·D W Self, E J Nestler
Jan 28, 1999·Neurology·J M GorellE L Peterson
May 5, 1999·Neurology·C MerchantR Mayeux
Jul 1, 1999·The Psychiatric Clinics of North America·W C Gamberino, M S Gold
Dec 22, 1999·Neurology·A OttM M Breteler
Apr 4, 2000·Neurology·Z GuoL A Farrer
Apr 25, 2000·BMJ : British Medical Journal·R DollI Sutherland
Mar 29, 2001·Neurology·D AarslandP Kragh-Sørensen

❮ Previous
Next ❯

Citations

Sep 3, 2002·Annals of Neurology·Karen Marder, Giancarlo Logroscino
Mar 27, 2004·Current Treatment Options in Neurology·Karen E. Anderson
Jul 10, 2003·Lancet Neurology·Murat Emre
May 18, 2010·Alzheimer Disease and Associated Disorders·Seung-Jae LeeKwang-Soo Lee
Feb 26, 2004·Lancet Neurology·Suzanne Craft, G Stennis Watson
Mar 25, 2004·The Canadian Journal of Neurological Sciences. Le Journal Canadien Des Sciences Neurologiques·Richard Camicioli, Nancy Fisher
Apr 25, 2006·Acta Neurologica Scandinavica·S PapapetropoulosD C Mash
Sep 30, 2015·Aging & Mental Health·Maxime DoironMartine Simard
Jun 4, 2016·Translational Neurodegeneration·Yaqian XuHuifang Shang
Aug 12, 2009·Neuroscience and Biobehavioral Reviews·Peter DomeZoltan Rihmer
Sep 23, 2003·Movement Disorders : Official Journal of the Movement Disorder Society·Murat Emre
Sep 17, 2004·Movement Disorders : Official Journal of the Movement Disorder Society·Guido AlvesJan P Larsen
Feb 3, 2007·Movement Disorders : Official Journal of the Movement Disorder Society·Marc G WeisskopfAlberto Ascherio
Feb 27, 2010·Movement Disorders : Official Journal of the Movement Disorder Society·Karen Marder
Jun 5, 2010·Brain Pathology·Dag Aarsland, Martin Wilhelm Kurz
Mar 15, 2019·Movement Disorders : Official Journal of the Movement Disorder Society·Yu GuoJin-Tai Yu
Feb 19, 2016·Journal of Alzheimer's Disease : JAD·Andrea PilottoAlessandro Padovani
Aug 4, 2018·Frontiers in Endocrinology·Carola RotermundJulia C Fitzgerald
Apr 10, 2020·Parkinson's Disease·Congcong FangBaohui Liu
Oct 5, 2021·Prague Medical Report·Jamir Pitton RissardoÍcaro Durante

❮ Previous
Next ❯

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.

Related Papers

Movement Disorders : Official Journal of the Movement Disorder Society
Marc G WeisskopfAlberto Ascherio
Movement Disorders : Official Journal of the Movement Disorder Society
Spiridon PapapetropoulosDeborah C Mash
Journal of Clinical Neuroscience : Official Journal of the Neurosurgical Society of Australasia
W G ReidP M Williamson
Dementia and Geriatric Cognitive Disorders
Martin KurzDag Aarsland
© 2022 Meta ULC. All rights reserved